Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 23, 2010

DeveloGen and Istituto Raffaele Win $500K JDRF Grant for R&D in Beta-Cell Regeneration

  • DeveloGen garnered a $500,000 grant from the Juvenile Diabetes Research Foundation to fund a project focused on developing new approaches to protecting insulin-producing beta cells. The work will be carried out in partnership with the Istituto San Raffaele in Milan.

    DeveloGen is focused on the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders, in particular diabetes. The firm’s aim is to identify and exploit mechanisms involved in the dynamic regulation of beta-cell mass to develop drugs that stimulate the regeneration or protection of beta cells in diabetic patients.

    In 2006, DeveloGen received its first grant from JDRF to support the development of new approaches to beta-cell regeneration. The firm claims ongoing research has identified novel secreted factors from early embryonic stages of pancreas development that demonstrate the ability to stimulate beta-cell differentiation and/or proliferation.   

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »